Skip to main content

Table 4 Clinical, functional, and laboratory data at baseline and at 3, 6, and 12 months of treatment

From: Real-life cost-effectiveness of benralizumab in patients with severe asthma

Variables

Baseline

3 months

6 months

12 months

p*

ACT, mean (SD)

13.7 (4.1)

20.1 (3.6)

20.8 (2.9)

21.3 (2.2)

< 0.001

Controlled asthma (ACT ≥ 20), n (%)

2 (4.5)

25 (56.8)

36 (81.8)

39 (92.9)

< 0.001

Number of ED visits in the previous year, mean (SD)

4.1 (2.6)

0.7 (1.6)

< 0.001

Number of severe exacerbations in the previous year, mean (SD)

5.50 ± 2.63

0.66 ± 0.94

< 0.001

Corticosteroid-dependent, n (%)

18 (40.9)

16 (36.4)

9 (20.5)

8 (18.2)

< 0.001

Inhaled budesonide (or equivalent) dose, μg/day, mean (SD)

993 (485)

853 (446)

773 (408)

693 (343)

< 0.001

Oral prednisone dose, mg/day, mean (SD)

19.3 (8.8)

10 (8.6)

5.3 (7.8)

3.9 (7.2)

< 0.001

Number of courses of OCS (previous year), mean (SD)

5.8 (3.3)

1 (1.6)

< 0.001

FEV1 mL, mean (SD)

1459 (509)

1697 (495)

1732 (621)

1833 (556)

< 0.001

FEV1%, mean (SD)

66.1 (14)

74.3 (12.2)

77 (14.5)

78.3 (15)

< 0.001

Blood eosinophil count, cells/μL, mean (SD)

730.9 (288)

18 (18)

14.9 (13.7)

2.7 (4)

< 0.001

  1. ACT asthma control test, ED emergency department, FEV1 forced expiratory volume in 1 s, OCS oral corticosteroids, SD standard deviation
  2. *Comparison between data at baseline and at 12 months